Beyond Biotech Podcast: Mainz Biomed

Show Notes

2:18 news
3: 46 Mainz Biomed

This week, we have a conversation with Mainz Biomed CEO, Guido Bächler.

Mainz Biomed Provides Year-End 2022 Corporate Review

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its corporate summary for the fiscal year ended December 31, 2022.

The company launched its U.S.-based eAArly DETECT study by enrolling the first patient; study focused on the performance of Mainz Biomed’s mRNA biomarkers in identifying advance adenomas (AA), a type of pre-cancerous polyp often attributed to colorectal cancer (CRC); on track to report results in 1H 2023.

It also Initiated ReconAAsense, a U.S. pivotal clinical study with company’s CRC screening test, anticipating commencing patient enrollment in mid-2023.

Mainz Biomed also ramped up international commercial activities for ColoAlert, the company’s highly efficacious and easy-to-use detection test for CRC, including five new lab partners in Germany and Italy.

It also Initiated and commenced patient enrollment in ColoFuture, a European study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert; potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC; with results expected in 2023.

“The past year has proven to be an extraordinary period of growth as we strengthened every aspect of the Company while expanding our international commercial footprint and executing our product development programs,” said Guido Baechler, CEO of Mainz Biomed.

“We head into 2023 with a great deal of momentum, and on behalf of the management team and Board of Directors, I wish to extend gratitude to our shareholders for their support as we continue our journey to become a leading provider of cancer-focused early detection and disease prevention molecular diagnostics.”


Originally broadcast at




This field is for validation purposes and should be left unchanged.